Figure 3.Hierarchical classification of the International Consensus Classification of AML. AML—Acute Myeloid Leukemia, ASXL1—Additional Sex Combs Like 1, BCOR—BCL6 Corepressor, EZH2—Enhancer of Zeste Homolog 2, MDS—Myelodysplastic Syndrome, MPN—Myeloproliferative Neoplasm, RUNX1—Runt-Related Transcription Factor 1, SF3B1—Splicing Factor 3b Subunit 1, SRSF2—Serine/Arginine-Rich Splicing Factor 2, STAG2—Stromal Antigen 2, TP53—Tumor Protein 53, U2AF1—U2 Small Nuclear RNA Auxiliary Factor 1, VAF—Variant Allele Frequency, ZRSR2—Zinc Finger CCCH-Type, RNA-Binding Motif and Serine/Arginine-Rich 2|@|~(^,^)~|@|2022 ELN risk classification by genetics at initial diagnosis. AML—Acute Myeloid Leukemia, ASXL1—Additional Sex Combs Like 1, BCOR—BCL6 Corepressor, CEBPA—CCAAT Enhancer Binding Protein Alpha, CREBBP—CREB Binding Protein, EZH2—Enhancer of Zeste Homolog 2, FLT3-ITD—FMS-like Tyrosine Kinase 3-Internal Tandem Duplication, GATA2—GATA Binding Protein 2, KMT2A—Lysine Methyltransferase 2A, MEF2C—Myocyte Enhancer Factor 2C, MLLT3—Myeloid/Lymphoid or Mixed-Lineage Leukemia Translocated to 3, MYH11—Myosin Heavy Chain 11, NPM1—Nucleophosmin 1, NUP214—Nucleoporin 214, RUNX1—Runt-Related Transcription Factor 1, SF3B1—Splicing Factor 3b Subunit 1, SRSF2—Serine/Arginine-Rich Splicing Factor 2, STAG2—Stromal Antigen 2, TP53—Tumor Protein 53, U2AF1—U2 Small Nuclear RNA Auxiliary Factor 1, ZRSR2—Zinc Finger CCCH-Type, RNA-Binding Motif and Serine/Arginine-Rich 2|@|~(^,^)~|@|a b Treatment Algorithm for Newly diagnosed patients with AML fit for intensive therapy. AML—Acute Myeloid Leukemia, CBF—Core Binding Factor, CK—Complex Karyotype, CPX351—Liposomal Daunorubicin and Cytarabine, FLT3—FMS-like Tyrosine Kinase 3, GO—Gemtuzumab Ozogamicin, HMA—Hypomethylating Agents, tAML—Therapy-Related Acute Myeloid Leukemia, AML-MR—Acute Myeloid Leukemia with Myelodysplasia-Related Changes, TP53—Tumor Protein 53, Ven—Venetoclax

© Blood Research